Ireland - English - HPRA (Health Products Regulatory Authority)

fannin limited - epirubicin - solution for inj/inf - 2 mg/ml - anthracyclines and related substances

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - epirubicin hydrochloride 2 mg/ml;   - solution for injection - 2 mg/ml - active: epirubicin hydrochloride 2 mg/ml   excipient: hydrochloric acid sodium chloride water for injection - epirubicin hydrochloride has produced responses in a wide spectrum of neoplastic diseases, and is indicated for the treatment of breast cancer, gastric cancer, ovarian cancer, small cell lung cancer, lymphoma (non-hodgkin's lymphoma), advanced/ metastatic soft tissue sarcoma, and superficial bladder cancer (tis, ta). in bladder cancer, epirubicin hydrochloride is also indicated in the prophylaxis of recurrence after transurethral resection of stage t1 papillary cancers and stage ta multifocal papillary cancers (grade 2 and 3).

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - epirubicin hydrochloride, quantity: 200 mg - injection, solution - excipient ingredients: sodium chloride; dilute hydrochloric acid; water for injections - epirubicin has produced responses in a wide spectrum of neoplastic diseases, and is indicated for the treatment of breast cancer, gastric cancer, ovarian cancer, small cell lung cancer, lymphoma (non-hodgkin's lymphoma), advanced/ metastatic soft tissue sarcoma, and superficial bladder cancer (tis, ta). in bladder cancer, epirubicin is also indicated in the prophylaxis of recurrence after transurethral resection of stage t1 papillary cancers and stage ta multifocal papillary cancers (grade 2 and 3).

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - epirubicin hydrochloride, quantity: 100 mg - injection, solution - excipient ingredients: sodium chloride; dilute hydrochloric acid; water for injections - epirubicin has produced responses in a wide spectrum of neoplastic diseases, and is indicated for the treatment of breast cancer, gastric cancer, ovarian cancer, small cell lung cancer, lymphoma (non-hodgkin's lymphoma), advanced/ metastatic soft tissue sarcoma, and superficial bladder cancer (tis, ta). in bladder cancer, epirubicin is also indicated in the prophylaxis of recurrence after transurethral resection of stage t1 papillary cancers and stage ta multifocal papillary cancers (grade 2 and 3).

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - epirubicin hydrochloride, quantity: 50 mg - injection, solution - excipient ingredients: water for injections; dilute hydrochloric acid; sodium chloride - epirubicin has produced responses in a wide spectrum of neoplastic diseases, and is indicated for the treatment of breast cancer, gastric cancer, ovarian cancer, small cell lung cancer, lymphoma (non-hodgkin's lymphoma), advanced/ metastatic soft tissue sarcoma, and superficial bladder cancer (tis, ta). in bladder cancer, epirubicin is also indicated in the prophylaxis of recurrence after transurethral resection of stage t1 papillary cancers and stage ta multifocal papillary cancers (grade 2 and 3).

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - epirubicin hydrochloride, quantity: 10 mg - injection, solution - excipient ingredients: water for injections; dilute hydrochloric acid; sodium chloride - epirubicin has produced responses in a wide spectrum of neoplastic diseases, and is indicated for the treatment of breast cancer, gastric cancer, ovarian cancer, small cell lung cancer, lymphoma (non-hodgkin's lymphoma), advanced/ metastatic soft tissue sarcoma, and superficial bladder cancer (tis, ta). in bladder cancer, epirubicin is also indicated in the prophylaxis of recurrence after transurethral resection of stage t1 papillary cancers and stage ta multifocal papillary cancers (grade 2 and 3).

Israel - English - Ministry of Health

novartis israel ltd - epirubicin hydrochloride - concentrate for solution for infusion - epirubicin hydrochloride 2 mg/ml - epirubicin - for the treatment of wide spectrum of neoplastic diseases including breast carcinoma, lung carcinoma (high doses), ovarian carcinoma, gastric carcinomas, soft tissue sarcoma. intravesical administration of farmorubicin has been found to be beneficial in the treatment of superficial bladder carcinomas and in the prophylaxis of recurrences after stransurethral resection. i.v. administration for the treatment of advanced bladder carcinoma.

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

ebewe pharma, austria - epirubicin hydrochloride - concentrate for solution for infusion - 2 mg/ml

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

ebewe pharma, austria - epirubicin hydrochloride - concentrate for solution for infusion - 2 mg/ml

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

ebewe pharma, austria - epirubicin hydrochloride - concentrate for solution for infusion - 2 mg/ml